ACADIA Pharmaceuticals Inc. (ACAD) News

ACADIA Pharmaceuticals Inc. (ACAD): $16.40

0.66 (+4.19%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter ACAD News Items

ACAD News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

ACAD News Highlights

  • For ACAD, its 30 day story count is now at 9.
  • Over the past 20 days, the trend for ACAD's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • DRUG, ORIC and ADP are the most mentioned tickers in articles about ACAD.

Latest ACAD News From Around the Web

Below are the latest news stories about Acadia Pharmaceuticals Inc that investors may wish to consider to help them evaluate ACAD as an investment opportunity.

Acadia's NUPLAZID, FDA's Second Chance To Get Alzheimer's Right

Acadia (ACAD) has been suffering from the FDA's CRL beatdown of its poorly designed, overly aggressive NUPLAZID (pimavanserin) clinical trial. The FDA has been suffering from blowback on its overly broad and poorly conceived ADUHELM (aducanumab) approval in treatment of Alzheimer's disease [AD]. Acadia has revised and resubmitted its NUPLAZID...

Out of Ignorance on Seeking Alpha | February 22, 2022

Will Acadia Pharmaceuticals (ACAD) Report Negative Earnings Next Week? What You Should Know

Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | February 21, 2022

The past year for ACADIA Pharmaceuticals (NASDAQ:ACAD) investors has not been profitable

ACADIA Pharmaceuticals Inc. ( NASDAQ:ACAD ) shareholders will doubtless be very grateful to see the share price up 45...

Yahoo | February 17, 2022

Acadia Pharmaceuticals Announces Resubmission of Supplemental New Drug Application to U.S. FDA for NUPLAZID® (pimavanserin) to Treat Alzheimer’s Disease Psychosis

SAN DIEGO, February 16, 2022--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that it has resubmitted its supplemental New Drug Application (sNDA) for pimavanserin for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP) to the U.S. Food and Drug Administration (FDA).

Yahoo | February 16, 2022

Here's How Much a $1000 Investment in Acadia Pharmaceuticals Made 10 Years Ago Would Be Worth Today

Holding on to popular or trending stocks for the long-term can make your portfolio a winner.

Yahoo | February 16, 2022

Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2021 Financial Results on February 28, 2022

SAN DIEGO, February 14, 2022--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report fourth quarter and full year 2021 financial results on Monday, February 28, 2022, after the close of the U.S. financial markets. Acadia’s management team will also host a conference call and webcast on February 28, 2022, at 4:30 p.m. Eastern Time to discuss financial results and operations.

Yahoo | February 14, 2022

Acadia Pharmaceuticals to Present at the 11th Annual SVB Leerink Global Healthcare Conference on February 18, 2022

SAN DIEGO, February 11, 2022--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 11th Annual SVB Leerink Global Healthcare Conference on Friday, February 18, 2022, at 1:40 p.m. Eastern Time.

Yahoo | February 11, 2022

Emerald Advisers, Llc Buys Customers Bancorp Inc, Herc Holdings Inc, ACADIA Pharmaceuticals ...

Investment company Emerald Advisers, Llc (Current Portfolio) buys Customers Bancorp Inc, Herc Holdings Inc, ACADIA Pharmaceuticals Inc, HireRight Holdings Corp, Arhaus Inc, sells Chegg Inc, ORIC Pharmaceuticals Inc, BellRing Brands Inc, Trex Co Inc, Arena Pharmaceuticals Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Emerald Advisers, Llc.

Yahoo | February 2, 2022

Emerald Mutual Fund Advisers Trust Buys Customers Bancorp Inc, Herc Holdings Inc, ACADIA ...

Leola, PA, based Investment company Emerald Mutual Fund Advisers Trust (Current Portfolio) buys Customers Bancorp Inc, Herc Holdings Inc, ACADIA Pharmaceuticals Inc, Karuna Therapeutics Inc, HireRight Holdings Corp, sells Chegg Inc, BellRing Brands Inc, Echo Global Logistics Inc, Tetra Tech Inc, ORIC Pharmaceuticals Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Emerald Mutual Fund Advisers Trust.

Yahoo | February 2, 2022

Acadia (ACAD) Up More Than 20% in Past 3 Months: Here's Why

Acadia's (ACAD) Nuplazid, approved for treating hallucinations and delusions associated with Parkinson's disease psychosis, has seen strong uptake so far. Its label expansion studies also hold promise.

Yahoo | January 13, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.463 seconds.